Dramatic response of teratoma-associated non-germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor

Michael S. Gordon, Linda A. Battiato, David Finch, Robert Goulet, Lawrence H. Einhorn

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

A patient with nonseminomatous germ cell cancer, treated with standard chemotherapy, subsequently developed a pathologically confirmed metastatic undifferentiated adenocarcinoma (non-germ-cell elements) arising from residual teratoma. Disease was present in both lobes of the liver and was deemed unresectable at the time of presentation. The patient was treated on a National Cancer Institute-sponsored institutional protocol with all-trans retinoic acid. After 60 days of oral therapy at a dose of 150 mg/m2/d (50 mg/m2 three times daily), the patient was found to have complete radiologic resolution of his hepatic metastases. He subsequently underwent surgery and his complete response was pathologically confirmed.

Original languageEnglish (US)
Pages (from-to)269-271
Number of pages3
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume24
Issue number3
DOIs
StatePublished - Jun 21 2001

Keywords

  • All-trans retinoic acid
  • Non-germ-cell cancer
  • Teratoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Dramatic response of teratoma-associated non-germ-cell cancer with all-trans retinoic acid in a patient with nonseminomatous germ cell tumor'. Together they form a unique fingerprint.

Cite this